Anti Vegf Eylea Hd denied for failing step therapy by Humana?

Humana's specific coverage criteria for anti vegf eylea hd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applies Step Therapy to Eylea HD

Humana's step-therapy (also called "fail-first") policy for Eylea HD (high-dose aflibercept) typically requires that a patient first try and fail one or more lower-cost anti-VEGF agents before Eylea HD will be covered. The denial is issued when either (a) no step-therapy trial was documented, or (b) the documentation submitted did not clearly show that the required prior agent was tried at an adequate duration or frequency and produced an inadequate clinical response. This is one of the most common — and most successfully appealed — denial types for retinal anti-VEGF therapy.

## Why This Denial Is Appealable

Step-therapy protocols must include a process for exceptions. Under step-therapy reform laws (enacted in many states and applicable under federal guidance to self-funded plans) and under the ACA, a plan must grant a step-therapy exception when the required prior drug is contraindicated, when it was previously tried and failed, or when requiring its trial would cause clinically significant harm. If your chart already documents prior anti-VEGF therapy, the denial may rest on a documentation gap rather than a genuine failure to meet the protocol.

## Federal Appeal Framework

• Step-therapy exception request: File this alongside or prior to the internal appeal; most plans have a separate, expedited exception pathway.
• Internal appeal (ERISA §503 / ACA §2719): Submit within the timeframe on the denial letter.
• External review: Available through an accredited IRO after final internal denial, generally within four months.
• Expedited review: Request 72-hour expedited processing in writing if active disease poses risk of irreversible vision loss while the appeal is pending.

## Concrete Appeal Steps and Timeline

1. Obtain Humana's current step-therapy policy for aflibercept; identify the required prior-step agent(s), the required trial duration, and the documented-failure standard. 2. Pull the patient's chart for all prior anti-VEGF administrations — dates, drug names, injection frequencies, and recorded visual-acuity and imaging outcomes. 3. If prior therapy was completed: compile a chronological summary with chart references showing inadequate response. 4. If prior therapy was not done: determine whether a clinical exception applies (e.g., the prior-step drug is not appropriate for this patient's specific condition or comorbidity profile) and have the ophthalmologist document that rationale. 5. Submit the step-therapy exception and internal appeal with imaging, visit notes, and prescriber letter. 6. Request expedited review with documentation of active disease urgency.

## Documentation to Gather

• Prior anti-VEGF treatment history: Exact dates, drug names, number of injections, and OCT/visual-acuity outcomes at each timepoint.
• Inadequate-response documentation: Chart notes specifically recording persistent or recurrent disease activity despite prior therapy.
• Clinical-exception rationale (if applicable): Prescriber's written explanation of why the step-therapy requirement should be waived for this patient, citing specific chart findings.
• Humana step-therapy policy: The current document listing required prior-step agents and exception criteria.
• FDA prescribing information for Eylea HD: Relevant sections supporting the clinical basis for selection of this agent.

## Criteria-Mapping Structure

List each step-therapy requirement from Humana's policy in a table. In the adjacent column, record the specific chart evidence — injection dates, imaging findings at each follow-up, recorded visual-acuity values — that documents prior-step completion and inadequate response, or the clinical basis for an exception. Attach labeled chart excerpts as exhibits.